Press Center: News

On the threshold of its 20th anniversary, Lidings is implementing the next stage in the evolution of its management model.

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2026 the firm is ranked among the TOP leading legal advisors in Russia. 

Lidings’ Intellectual Property practice team succeeded in obtaining cancellation of registration of a drug in a dispute against the holder of the marketing authorisation (MA) due to the fact that during the process of registration of a generic drug product the Ministry of Health of Russia received false information from the holder of the MA.

We are delighted to announce that Lidings has updated The Pharma Legal Handbook: Russia - practical directory focused on the key aspects of legislative regulation of pharmaceutical industry in Russia.

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2024 the firm is ranked among the TOP leading legal advisors in Russia. 

Lidings’ IP team has successfully secured recognition of the Doppelherz brand as a well-known trademark specifically for dietary supplements, setting a valuable precedent. The interests of the client, the German pharmaceutical company Queisser Pharma, which owns the brand, were represented by Boris Malakhov, Partner, and Vladislav Ryabov, Senior Associate.

Lidings Intellectual Property team has helped a major Russian manufacturer of pharmaceuticals, Pharmnovations, to achieve the annulment of the marketing authorization for a generic drug of a competitor company.

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2023 the firm is ranked among the TOP leading legal advisors in Russia. 

Restriction Impossible to be Registered: Lidings Team Defends Interests of Major Russian Pharmaceutical Manufacturer in Patent Dispute Over Registration of Generic.